Possible Benefits of Metformin for Lung Cancer Still Unknown
Leah LawrenceBen Levy, MD When it comes to the use of metformin as a treatment for lung cancer, the jury is still out on its potential. “Metformin’s utility as an anticancer […] Read more
RET Therapy for NSCLC, a New Generation of Inhibitors
Karen L. ReckampTherapies for NSCLC have evolved over the past 2 decades to account for the specific biology of the tumor and have improved outcomes for a multitude of patients. Discovery of […] Read more
Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies
Misako Nagasaka+more
When patients with advanced metastatic NSCLC initially make their way into our medical oncology clinic, one of the first things we check for is the molecular pathology testing report, in […] Read more
Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD
Marcelo V. NegraoDr. Negrao is an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center. Dr. Negrao has a diverse experience in […] Read more
Christine Lovly, MD, PhD Christine Lovly, MD, PhD, and Helena Yu, MD, have been awarded the 2021 EGFR Resisters/LUNGevity Lung Cancer Research Award. Each award totals $200,000 for a two-year […] Read more
Mary Jo Fidler, MD
Mary Jo Fidler, MD, is now Section Chief for Section of Medical Oncology at Rush Medical College. She has been on staff in medical oncology at RUSH since 2007. Dr. […] Read more
Premonitions About Lung Cancer for the Next Decade
Ramón Rami-Porta, MDDaniel Kahneman, PhD, was awarded the Nobel Prize in 2002 for proving, among other things, that intuitions—even expert ones—fail and that formulas based on data fare better. Intuitions are more […] Read more
Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer
Ling Peng, MD, PhD+more
HER2 can be aberrantly expressed in NSCLC, caused by its mutation and/or amplification.1 Like in breast cancer, patients with NSCLC with somatic HER2 mutations rarely show concurrent gene amplification, highlighting […] Read more
February 3, 2021—Tepotinib was approved for treatment of patients with metastatic NSCLC who harbor MET exon 14 skipping alterations. Approval was based on data from the VISION trial (NCT02864992). VISION, […] Read more
All information and materials presented on or through IASLC’s websites, or made available or provided by or on behalf of IASLC during any webinar, seminar, or other event or activity, […] Read more